Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.45 |
| ▸ | PIK3C2B | O00750 | 17/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.41 |
| ▸ | MTOR | P42345 | 13/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078709 | 0.89 | PIK3CD (0.44) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736988 | 0.83 | SUV39H2 (0.32) | — | |
| SCHEMBL19736721 | 0.82 | PIK3CD (0.48) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19913030 | 0.81 | PIK3CB (0.55) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736618 | 0.80 | PIK3CD (0.44) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736715 | 0.79 | PIK3CD (0.41) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736614 | 0.79 | PIK3CD (0.46) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736831 | 0.78 | PIK3CD (0.58) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736866 | 0.78 | PIK3CD (0.46) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL17856984 | 0.77 | PIK3CD (0.57) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-19 | — | — | US | disclosed |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| WO-2017216292-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3C2B 7/4885PIK3CG 5/4885 |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3C2B 7/4885PIK3CG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.